Skip to main content
J

Jiangxi Sanxin Medtec Co.,Ltd. — Investor Relations & Filings

Ticker · 300453 LEI · 836800E8MVDVV6772007 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,439 across all filing types
Latest filing 2026-04-26 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300453

About Jiangxi Sanxin Medtec Co.,Ltd.

https://www.sanxin-med.com

Jiangxi Sanxin Medtec Co.,Ltd. specializes in the research, development, manufacturing, and distribution of medical consumables and equipment. The company's primary product portfolio focuses on blood purification, including hemodialyzers, blood tubing sets, and dialysis concentrates. Additionally, it produces a wide range of sterile medical devices such as safety syringes, auto-disable syringes, venous catheters, and infusion sets. The organization emphasizes technological innovation and quality control, maintaining an integrated production chain for dialysis treatments. Its products are designed to meet international safety standards, serving healthcare providers in both domestic and global markets with a focus on infection prevention and patient care efficiency.

Recent filings

Filing Released Lang Actions
董事会对于独立董事独立性自查情况的专项意见
Governance Information Classification · 1% confidence The document is a Board-issued special opinion on the self-assessment of independent directors’ independence, referencing corporate governance rules and stock exchange guidelines. It is not announcing a change or financial results but addresses the company’s internal governance practices regarding board composition and independence. Therefore, it falls under Governance Information (CGR).
2026-04-26 Chinese
独立董事2025年度述职报告（蒋海洪)
Regulatory Filings Classification · 1% confidence The document is an independent director’s 2025 annual performance report, detailing his duties, meetings attended, and compliance with governance rules. It is neither an AGM presentation, dividend notice, earnings release, nor a notice of appointment/resignation only. There is no dedicated category for an independent director’s report in the taxonomy. It does not merely announce publication of another report, nor fit any specific financial, legal, or capital update category. Therefore it falls under the fallback category “Regulatory Filings” (RNS).
2026-04-26 Chinese
章程修订对照表
Governance Information Classification · 1% confidence The document is a detailed comparison table of amendments to the company's Articles of Association (“章程修订对照表”), outlining governance structure changes, board composition rules, and committee responsibilities. It is not an AGM presentation, earnings release, or proxy statement, but rather a governance information document detailing internal rules and board/governance structure updates. This fits the Governance Information category.
2026-04-26 Chinese
董事会议事规则（2026年4月）
Governance Information Classification · 1% confidence The document is the full text of the company’s "Board of Directors Rules of Procedure," detailing board composition, duties, meeting procedures, committees, and governance principles. It is a corporate governance manual, not an announcement or financial report. This matches the "Governance Information" category (CGR).
2026-04-26 Chinese
薪酬与考核委员会议事规则（2026年4月）
Governance Information Classification · 1% confidence The document is the formal ‘Meeting Rules’ for the Board’s Remuneration and Assessment Committee, detailing committee composition, duties, meeting procedures, evaluation processes, and internal governance protocols. It is an internal governance charter rather than a financial report, announcement, or external filing. This matches the definition of Governance Information (Code: CGR).
2026-04-26 Chinese
关于2026年度融资计划的公告
Capital/Financing Update Classification · 1% confidence The document is an official announcement by Jiangxi Sanxin Medical Technology Co., Ltd. regarding its 2026 annual financing plan, detailing the proposed debt financing limit (RMB 600 million), authorized instruments (bank loans, collateralized loans, bank acceptance bills), board approval details, and committee opinions. It pertains directly to the company’s financing activities rather than financial results, share issues, or regulatory filings. Therefore, it fits the definition of a Capital/Financing Update.
2026-04-26 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.